NEUROGENE INC (NGNE) Stock Fundamental Analysis

NASDAQ:NGNE • US64135M1053

17.64 USD
-0.98 (-5.26%)
At close: Feb 20, 2026
17.64 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

NGNE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. NGNE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, NGNE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year NGNE has reported negative net income.
  • NGNE had a negative operating cash flow in the past year.
  • NGNE had negative earnings in each of the past 5 years.
  • NGNE had a negative operating cash flow in each of the past 5 years.
NGNE Yearly Net Income VS EBIT VS OCF VS FCFNGNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • With a decent Return On Assets value of -26.11%, NGNE is doing good in the industry, outperforming 70.25% of the companies in the same industry.
  • The Return On Equity of NGNE (-28.30%) is better than 77.54% of its industry peers.
Industry RankSector Rank
ROA -26.11%
ROE -28.3%
ROIC N/A
ROA(3y)-29.45%
ROA(5y)-28.26%
ROE(3y)-34.92%
ROE(5y)-32.93%
ROIC(3y)N/A
ROIC(5y)N/A
NGNE Yearly ROA, ROE, ROICNGNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NGNE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NGNE Yearly Profit, Operating, Gross MarginsNGNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • NGNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NGNE has more shares outstanding
  • NGNE has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for NGNE has been reduced compared to a year ago.
NGNE Yearly Shares OutstandingNGNE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
NGNE Yearly Total Debt VS Total AssetsNGNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • NGNE has an Altman-Z score of 5.88. This indicates that NGNE is financially healthy and has little risk of bankruptcy at the moment.
  • NGNE has a better Altman-Z score (5.88) than 74.28% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that NGNE is not too dependend on debt financing.
  • NGNE has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: NGNE outperforms 53.36% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.88
ROIC/WACCN/A
WACC8.72%
NGNE Yearly LT Debt VS Equity VS FCFNGNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 18.39 indicates that NGNE has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 18.39, NGNE belongs to the best of the industry, outperforming 95.01% of the companies in the same industry.
  • A Quick Ratio of 18.39 indicates that NGNE has no problem at all paying its short term obligations.
  • NGNE has a better Quick ratio (18.39) than 95.01% of its industry peers.
Industry RankSector Rank
Current Ratio 18.39
Quick Ratio 18.39
NGNE Yearly Current Assets VS Current LiabilitesNGNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 14.20% over the past year.
EPS 1Y (TTM)14.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • NGNE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.62% yearly.
  • The Revenue is expected to grow by 185.19% on average over the next years. This is a very strong growth
EPS Next Y-0.23%
EPS Next 2Y-11.54%
EPS Next 3Y-12.73%
EPS Next 5Y27.62%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y185.19%

3.3 Evolution

NGNE Yearly Revenue VS EstimatesNGNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2024 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
NGNE Yearly EPS VS EstimatesNGNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 2031 2032 2033 0 -20 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NGNE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGNE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGNE Price Earnings VS Forward Price EarningsNGNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGNE Per share dataNGNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

  • A cheap valuation may be justified as NGNE's earnings are expected to decrease with -12.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.54%
EPS Next 3Y-12.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NGNE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEUROGENE INC

NASDAQ:NGNE (2/20/2026, 8:00:01 PM)

After market: 17.64 0 (0%)

17.64

-0.98 (-5.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-23
Inst Owners104.75%
Inst Owner Change7.51%
Ins Owners8.5%
Ins Owner Change0%
Market Cap273.24M
Revenue(TTM)925.00K
Net Income(TTM)-75.14M
Analysts86.67
Price Target60.18 (241.16%)
Short Float %25.34%
Short Ratio22.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.75%
Min EPS beat(2)11.15%
Max EPS beat(2)22.35%
EPS beat(4)4
Avg EPS beat(4)12.01%
Min EPS beat(4)0.42%
Max EPS beat(4)22.35%
EPS beat(8)6
Avg EPS beat(8)4.78%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.46%
EPS NY rev (1m)0%
EPS NY rev (3m)11.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 295.4
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB 1.03
EV/EBITDA N/A
EPS(TTM)-4.11
EYN/A
EPS(NY)-5.31
Fwd EYN/A
FCF(TTM)-5.06
FCFYN/A
OCF(TTM)-4.99
OCFYN/A
SpS0.06
BVpS17.14
TBVpS17.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.11%
ROE -28.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.45%
ROA(5y)-28.26%
ROE(3y)-34.92%
ROE(5y)-32.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.37%
Cap/Sales 126.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.39
Quick Ratio 18.39
Altman-Z 5.88
F-Score3
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)35.41%
Cap/Depr(5y)127.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.81%
EPS Next Y-0.23%
EPS Next 2Y-11.54%
EPS Next 3Y-12.73%
EPS Next 5Y27.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y185.19%
EBIT growth 1Y-48.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-138.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-139.25%
OCF growth 3YN/A
OCF growth 5YN/A

NEUROGENE INC / NGNE FAQ

What is the fundamental rating for NGNE stock?

ChartMill assigns a fundamental rating of 3 / 10 to NGNE.


What is the valuation status of NEUROGENE INC (NGNE) stock?

ChartMill assigns a valuation rating of 0 / 10 to NEUROGENE INC (NGNE). This can be considered as Overvalued.


Can you provide the profitability details for NEUROGENE INC?

NEUROGENE INC (NGNE) has a profitability rating of 1 / 10.


Can you provide the financial health for NGNE stock?

The financial health rating of NEUROGENE INC (NGNE) is 6 / 10.